Scroll

adenosine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	90	58-61-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: adenosine adenine riboside riboadenosine beta-Adenosine beta-D-Adenosine adenoscan	A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Molecular weight: 267.25 Formula: C10H13N5O4 CLOGP: -1.36 LIPINSKI: 0 HAC: 9 HDO: 4 TPSA: 139.54 ALOGS: -1.28 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

adenosine
adenine riboside
riboadenosine
beta-Adenosine
beta-D-Adenosine
adenoscan

A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.

Molecular weight: 267.25
Formula: C10H13N5O4
CLOGP: -1.36
LIPINSKI: 0
HAC: 9
HDO: 4
TPSA: 139.54
ALOGS: -1.28
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
15	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.67 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.48 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Oct. 30, 1989	FDA	ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	66.85	22.60	123	2042	1044642	62442215
Pneumonia aspiration	58.90	22.60	27	2138	34513	63452344
Underdose	48.49	22.60	22	2143	27434	63459423
Supraventricular tachycardia	47.55	22.60	18	2147	14253	63472604
Ventricular tachycardia	45.00	22.60	19	2146	19960	63466897
Coma	43.10	22.60	27	2138	64337	63422520
Atrial fibrillation	41.00	22.60	33	2132	116603	63370254
Gastrooesophageal reflux disease	37.79	22.60	29	2136	95610	63391247
Exfoliative rash	31.88	22.60	9	2156	2838	63484019
Ventricular fibrillation	29.11	22.60	12	2153	11855	63475002
Bronchospasm	27.85	22.60	13	2152	17267	63469590
Toxic epidermal necrolysis	25.90	22.60	14	2151	25320	63461537
Arteriospasm coronary	24.79	22.60	8	2157	3960	63482897
Tachycardia	24.76	22.60	25	2140	118131	63368726
Cardiogenic shock	24.36	22.60	12	2153	17920	63468937
Somnolence	24.05	22.60	30	2135	178655	63308202
Tachycardia induced cardiomyopathy	23.86	22.60	4	2161	107	63486750
Ventricular asystole	23.82	22.60	4	2161	108	63486749
Hypotension	23.58	22.60	37	2128	272567	63214290
Alcohol use disorder	23.03	22.60	3	2162	12	63486845
Hepatic cytolysis	23.01	22.60	11	2154	15396	63471461

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchospasm	94.79	22.20	31	1761	10700	34944439
Oesophageal ulcer haemorrhage	65.48	22.20	11	1781	195	34954944
Drug ineffective	61.50	22.20	94	1698	456657	34498482
Ventricular tachycardia	49.26	22.20	25	1767	26554	34928585
Arteriospasm coronary	47.71	22.20	14	1778	3368	34951771
Supraventricular tachycardia	44.80	22.20	18	1774	11099	34944040
Mallory-Weiss syndrome	44.59	22.20	11	1781	1373	34953766
Immune effector cell-associated neurotoxicity syndrome	33.85	22.20	11	1781	3702	34951437
Ventricular fibrillation	32.35	22.20	18	1774	22936	34932203
Complex regional pain syndrome	31.43	22.20	7	1785	560	34954579
Gingival bleeding	30.51	22.20	12	1780	6988	34948151
Myositis	30.34	22.20	14	1778	12056	34943083
Rebound tachycardia	28.70	22.20	4	1788	18	34955121
Benign soft tissue neoplasm	28.43	22.20	5	1787	117	34955022
Cardiac arrest	27.48	22.20	29	1763	96130	34859009
Intracardiac mass	26.78	22.20	5	1787	165	34954974
Atrioventricular block complete	24.01	22.20	11	1781	9308	34945831
Drug ineffective for unapproved indication	23.96	22.20	15	1777	23700	34931439
Fibroma	22.66	22.20	5	1787	383	34954756

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchospasm	114.76	22.73	43	3590	24816	79715939
Drug ineffective	101.00	22.73	177	3456	1080736	78660019
Supraventricular tachycardia	81.01	22.73	32	3601	21238	79719517
Ventricular tachycardia	77.72	22.73	38	3595	41897	79698858
Arteriospasm coronary	72.43	22.73	22	3611	6694	79734061
Ventricular fibrillation	59.35	22.73	29	3604	31897	79708858
Oesophageal ulcer haemorrhage	54.75	22.73	11	3622	604	79740151
Atrial fibrillation	50.17	22.73	53	3580	197833	79542922
Underdose	38.50	22.73	22	3611	33129	79707626
Mallory-Weiss syndrome	37.97	22.73	11	3622	2841	79737914
Cardiac arrest	36.49	22.73	42	3591	172054	79568701
Pneumonia aspiration	35.00	22.73	27	3606	66940	79673815
Exfoliative rash	34.69	22.73	11	3622	3848	79736907
Tachycardia induced cardiomyopathy	32.92	22.73	6	3627	195	79740560
Drug ineffective for unapproved indication	32.01	22.73	23	3610	51215	79689540
Immune effector cell-associated neurotoxicity syndrome	30.21	22.73	11	3622	5837	79734918
Benign soft tissue neoplasm	28.63	22.73	5	3628	127	79740628
Atrioventricular block complete	27.63	22.73	14	3619	16596	79724159
Cardiogenic shock	26.60	22.73	19	3614	41895	79698860
Intracardiac mass	25.83	22.73	5	3628	226	79740529
Myositis	25.74	22.73	14	3619	19154	79721601
Coma	25.53	22.73	27	3606	100622	79640133
Gingival bleeding	25.00	22.73	13	3620	16263	79724492
Complex regional pain syndrome	23.33	22.73	7	3626	2041	79738714
Gastrooesophageal reflux disease	23.01	22.73	26	3607	104220	79636535

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01EB10	CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations
MeSH PA	D000700	Analgesics
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D058913	Purinergic Agonists
MeSH PA	D058906	Purinergic P1 Receptor Agonists
MeSH PA	D018689	Sensory System Agents
MeSH PA	D014665	Vasodilator Agents
FDA MoA	N0000175788	Adenosine Receptor Agonists
FDA EPC	N0000178375	Adenosine Receptor Agonist
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:38070	antiarrhythmic agent
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:78675	fundamental metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Paroxysmal supraventricular tachycardia	indication	67198005
Myocardial Perfusion Imaging Adjunct	indication
Supraventricular tachycardia	off-label use	6456007
Pericarditis	contraindication	3238004	DOID:1787
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Disorder of autonomic nervous system	contraindication	15241006
Complete atrioventricular block	contraindication	27885002
Hypovolemia	contraindication	28560003
Acute cerebrovascular insufficiency	contraindication	29322000
Transplantation of heart	contraindication	32413006
Sick sinus syndrome	contraindication	36083008	DOID:13884
Low blood pressure	contraindication	45007003
Aortic valve stenosis	contraindication	60573004	DOID:1712
Left to right cardiovascular shunt	contraindication	66130006
Mitral valve stenosis	contraindication	79619009	DOID:1754
Pulmonary emphysema	contraindication	87433001
Respiratory alkalosis	contraindication	111378004
Second degree atrioventricular block	contraindication	195042002
Asthma	contraindication	195967001	DOID:2841
Left main coronary artery disease	contraindication	371804009
Acute coronary syndrome	contraindication	394659003
Respiratory insufficiency	contraindication	409623005
Syncope due to Bradycardia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.67	acidic
pKa2	12.33	acidic
pKa3	13.34	acidic
pKa4	3.95	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN	AGONIST	EC50	6.16	WOMBAT-PK	CHEMBL
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN	AGONIST	EC50	6.51	WOMBAT-PK	CHEMBL
Adenosine receptor A2b	GPCR	P29275	AA2BR_HUMAN	AGONIST	EC50	4.62	WOMBAT-PK	CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN	AGONIST	Ki	6.54	IUPHAR
Adenosine kinase	Kinase	P55263	ADK_HUMAN		IC50	6	WOMBAT-PK
Adenosine deaminase	Enzyme	P00813	ADA_HUMAN		Kd	4.60	WOMBAT-PK
Mitogen-activated protein kinase kinase kinase 7	Kinase	O43318	M3K7_HUMAN		Kd	5.36	CHEMBL
Adenosylhomocysteinase	Enzyme	P23526	SAHH_HUMAN		Km	5.80	WOMBAT-PK
Phosphatidylinositol 4-kinase type 2-alpha	Kinase	Q9BTU6	P4K2A_HUMAN	INHIBITOR	IC50	5	IUPHAR
Phosphatidylinositol 4-kinase type 2-beta	Kinase	Q8TCG2	P4K2B_HUMAN	INHIBITOR	IC50	5	IUPHAR
Glyceraldehyde-3-phosphate dehydrogenase liver	Enzyme	P04406	G3P_HUMAN		IC50	4.46	CHEMBL
Histone-lysine N-methyltransferase, H3 lysine-79 specific	Enzyme	Q8TEK3	DOT1L_HUMAN		IC50	4	CHEMBL
Adenosine receptor A1	GPCR		AA1R_RAT		Ki	8.29	CHEMBL
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	7.52	CHEMBL
Adenosine receptor A3	GPCR		AA3R_RAT		Ki	7	CHEMBL
Adenosine kinase	Kinase		ADK_TOXGO		Ki	5.05	CHEMBL
Adenosine A2 receptor	GPCR		AA2BR_RAT AA2AR_RAT		Ki	8.30	CHEMBL
cAMP-dependent protein kinase A	Kinase		KAP2_BOVIN KAPCA_BOVIN KAPCB_BOVIN KAP3_BOVIN		Ki	4.82	CHEMBL

External reference:

ID	Source
4019507	VUID
N0000147627	NUI
D00045	KEGG_DRUG
215025	RXNORM
C0001443	UMLSCUI
CHEBI:16335	CHEBI
ADN	PDB_CHEM_ID
CHEMBL477	ChEMBL_ID
DB00640	DRUGBANK_ID
D000241	MESH_DESCRIPTOR_UI
60961	PUBCHEM_CID
2844	IUPHAR_LIGAND_ID
K72T3FS567	UNII
108502004	SNOMEDCT_US
35431001	SNOMEDCT_US
4019507	VANDF
1072	MMSL
4135	MMSL
57772	MMSL
d00164	MMSL
003603	NDDF
004537	NDDF
004813	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9809	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	20 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9809	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	20 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9809	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	20 sections
ADENOSINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9993	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	13 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1932	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	25 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1932	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	25 sections
Adenocard	HUMAN PRESCRIPTION DRUG LABEL	1	0469-8234	SOLUTION	3 mg	INTRAVENOUS	NDA	17 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6113	INJECTION	3 mg	INTRAVENOUS	ANDA	21 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0703-8776	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	27 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0703-8777	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	27 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-180	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	27 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-556	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	25 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-972	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	27 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-997	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	25 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-542	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	21 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-542	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	21 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-542	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	21 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-544	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	26 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-544	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	26 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-953	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	20 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-953	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	20 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	23155-258	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	25 sections
Too im Cell ALL IN ONE	HUMAN OTC DRUG LABEL	3	24765-124	LOTION	0.40 mg	TOPICAL	OTC monograph not final	8 sections
adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	25021-301	INJECTION	3 mg	INTRAVENOUS	ANDA	23 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	25021-318	INJECTION	3 mg	INTRAVENOUS	ANDA	22 sections
Tissen NF 10	HUMAN OTC DRUG LABEL	1	42491-1100	LIQUID	0.01 g	TOPICAL	unapproved drug other	8 sections
Tissen ICM 10	HUMAN OTC DRUG LABEL	1	42491-1200	LIQUID	0.01 g	TOPICAL	unapproved drug other	8 sections
Dr G deWrinkle BOOSTER ample by EGF	HUMAN OTC DRUG LABEL	2	43948-3001	SOLUTION/ DROPS	0.04 mL	TOPICAL	OTC monograph final	8 sections
Dr G deWrinkle FORTIFIER by EGF	HUMAN OTC DRUG LABEL	2	43948-3002	CREAM	0.01 mL	TOPICAL	OTC monograph final	8 sections
Dr G deWrinkle REFORMER by EGF	HUMAN OTC DRUG LABEL	2	43948-3003	CREAM	0.02 mL	TOPICAL	OTC monograph final	8 sections